Search results
Results from the WOW.Com Content Network
Biotech company Dendreon (NAS: DNDN) and French pharma giant Sanofi (NYS: SNY) announced layoffs earlier this week. What do these staff reductions signify for the companies and investors? Let's ...
AMRI’s Allegra patent applications, from 1995, and the resulting patents were licensed to what is now Sanofi-Aventis. The company continues to receive royalties on the sale of Allegra and Telfast products globally. [23] In June 2014, AMRI acquired OsoBio Pharmaceuticals, a contract manufacturer specializing in aseptic filling, for $110 ...
French pharmaceutical company Sanofi-Aventis (SNY), which has been unsuccessful recently in its courtship of U.S. giant biotech Genzyme (GENZ), announced another setback today. Sanofi said a late ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
U.S. layoff announcements rose 7% in March to the highest since January 2023, led by technology and government-sector job eliminations, though cuts announced year to date are down 5% from a year ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.
(Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported ...
NEW YORK (Reuters) -Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a variety of new drugs and is not facing imminent ...